TNFSF11 and myocardial ischemia: Experimental studies in mice subjected to 60 min of myocardial ischemia and different reperfusion times up to 72 h showed that RANKL amounts are increased during reperfusion both in systemic circulation and infarcted hearts, and intravenous post-infarction anti-RANKL treatments reduce infarct size and cardiac neutrophil infiltration [124].